Hepatitis B e antigen negative – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatitis B e antigen negative – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Selgantolimod and NUC Discontinuation in Patients with Chronic Hepatitis B https://clinicaltrials.eu/trial/study-on-the-effects-of-selgantolimod-and-nuc-discontinuation-in-patients-with-chronic-hepatitis-b/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-selgantolimod-and-nuc-discontinuation-in-patients-with-chronic-hepatitis-b/ This clinical trial is focused on studying the treatment of Chronic Hepatitis B (CHB), a liver infection caused by the hepatitis B virus. The study involves several medications: Vemlidy (containing the active substance tenofovir alafenamide), Viread (containing tenofovir disoproxil), Baraclude (containing entecavir), and a new investigational drug called Selgantolimod (also known by its code name GS-9688). These medications are taken orally, either as film-coated tablets or as an oral solution.

The purpose of the study is to explore the effectiveness of stopping the use of nucleos(t)ide analogues (NUC), which are standard treatments for CHB, after treatment with Selgantolimod. The study will compare this approach to the continuous use of NUC over a period of 76 weeks. Participants will be divided into groups, with some continuing their NUC treatment and others stopping it after receiving Selgantolimod. The study aims to see if this new approach can lead to a significant reduction in the virus levels in the body.

Participants will be monitored over the course of the study, which lasts for about 76 weeks. During this time, they will have regular check-ups to assess their health and the levels of the virus in their blood. The study will also look at the overall health-related quality of life of the participants. The goal is to find out if the new treatment strategy can help manage Chronic Hepatitis B more effectively than the current standard of care.

]]> Study on the Effectiveness of Human Hepatitis B Immunoglobulin for Patients with Chronic Hepatitis B https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-hepatitis-b-immunoglobulin-for-patients-with-chronic-hepatitis-b/ Wed, 29 Apr 2026 14:58:23 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-hepatitis-b-immunoglobulin-for-patients-with-chronic-hepatitis-b/ This clinical trial is focused on studying chronic hepatitis B, a long-term infection of the liver caused by the hepatitis B virus. The study aims to evaluate the effectiveness of a treatment using specific immune antibodies known as hepatitis B immunoglobulins. These antibodies are designed to help the body fight the virus and potentially clear the infection. Two different forms of the treatment are being tested: Hepatect CP, which is given as an infusion directly into the bloodstream, and Zutectra, which is administered as an injection under the skin.

The purpose of the study is to assess how well these treatments work in helping patients with chronic hepatitis B become free of the virus. Participants will receive the treatment for a period of 12 weeks. During this time, the study will monitor the presence of the virus in the blood and any changes in liver health. The study will also look at the quality of life of participants during and after the treatment period.

Participants will be divided into two groups, or cohorts, based on their previous treatment history and current health status. The study will track the progress of the virus in each group, with a focus on whether the virus is no longer detectable in the blood by the end of the 12-week treatment. The study will also observe any changes in liver function and overall well-being during the treatment and follow-up period.

]]>